BACKGROUND/AIMS: Epidermal growth factor receptor (EGFR) has been considered as an attractive and potential therapeutic target of pancreatic cancer. However, the clinical importance of EGFR expression remains controversial. METHODS: We performed a meta-analysis of previous studies to quantitatively review the effects of EGFR expression on survival in patients with pancreatic cancer. RESULTS: Eight studies (570 patients) were included to perform a meta-analysis of the survival results. Overall, positivity for EGFR expression was 45.1% in pancreatic carcinoma. The combined hazard ratio was 1.225 (95% CI 1.014-1.481; p = 0.035), indicating that EGFR expression has a significant impact on survival. Heterogeneity was absent between studies and publication bias, which suggests that the summary statistics obtained may approximate the actual average. Three trials reported a survival disadvantage for patients with EGFR expression while five trials reported no statistically significant difference. CONCLUSION: EGFR expression is a poor prognostic factor for survival in patients with pancreatic cancer. and IAP.
BACKGROUND/AIMS: Epidermal growth factor receptor (EGFR) has been considered as an attractive and potential therapeutic target of pancreatic cancer. However, the clinical importance of EGFR expression remains controversial. METHODS: We performed a meta-analysis of previous studies to quantitatively review the effects of EGFR expression on survival in patients with pancreatic cancer. RESULTS: Eight studies (570 patients) were included to perform a meta-analysis of the survival results. Overall, positivity for EGFR expression was 45.1% in pancreatic carcinoma. The combined hazard ratio was 1.225 (95% CI 1.014-1.481; p = 0.035), indicating that EGFR expression has a significant impact on survival. Heterogeneity was absent between studies and publication bias, which suggests that the summary statistics obtained may approximate the actual average. Three trials reported a survival disadvantage for patients with EGFR expression while five trials reported no statistically significant difference. CONCLUSION:EGFR expression is a poor prognostic factor for survival in patients with pancreatic cancer. and IAP.
Authors: Amber L Johns; David K Miller; Skye H Simpson; Anthony J Gill; Karin S Kassahn; Jeremy L Humphris; Jaswinder S Samra; Katherine Tucker; Lesley Andrews; David K Chang; Nicola Waddell; Marina Pajic; John V Pearson; Sean M Grimmond; Andrew V Biankin; Nikolajs Zeps Journal: Genome Med Date: 2014-05-29 Impact factor: 11.117
Authors: Jacob Elebro; Margareta Heby; Carl Fredrik Warfvinge; Björn Nodin; Jakob Eberhard; Karin Jirström Journal: PLoS One Date: 2016-04-12 Impact factor: 3.240